American Century Companies Inc. Purchases 84,934 Shares of ADMA Biologics Inc $ADMA

American Century Companies Inc. increased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 1.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,695,923 shares of the biotechnology company’s stock after buying an additional 84,934 shares during the quarter. American Century Companies Inc. owned 1.97% of ADMA Biologics worth $68,842,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Salomon & Ludwin LLC bought a new stake in shares of ADMA Biologics in the third quarter worth about $25,000. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,495 shares in the last quarter. Clearstead Advisors LLC grew its position in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares during the period. Financial Consulate Inc. bought a new stake in ADMA Biologics during the 3rd quarter worth approximately $44,000. Finally, AlphaQuest LLC bought a new stake in ADMA Biologics during the 3rd quarter worth approximately $46,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of research reports. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and an average target price of $32.00.

ADMA Biologics Price Performance

Shares of ADMA opened at $16.54 on Thursday. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. ADMA Biologics Inc has a twelve month low of $13.76 and a twelve month high of $25.67. The stock has a market capitalization of $3.94 billion, a P/E ratio of 27.57 and a beta of 0.51. The company has a 50 day moving average of $17.07 and a 200-day moving average of $16.80.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting the consensus estimate of $0.20. The business had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.46 earnings per share. As a group, equities research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.